EVGN vs EYPT

Evogene Ltd. vs EyePoint, Inc. — Valuation Comparison 2026

EVGN

Biotechnology
Evogene Ltd.
Quality
1.9
out of 10
Value Trap
6
SAFE
Price
$0.72
Last close
Models
9/13
Active
VS

EYPT

Biotechnology
EyePoint, Inc.
Quality
5.6
out of 10
Value Trap
12
SAFE
Price
$13.50
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType EVGN Fair ValueEVGN Upside EYPT Fair ValueEYPT Upside
Bayesian DCF Intrinsic $0.19 -73.5% $4.03 -70.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.57 -19.4% $4.13 -69.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $4.11 +475.3% $0.84 -93.8%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for EVGN vs EYPT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EVGN vs EYPT — Which Stock Is More Undervalued?

EYPT scores higher with a 5.6/10 quality rating vs EVGN's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Evogene Ltd. (EVGN) and EyePoint, Inc. (EYPT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EVGN currently trades at $0.72 with a QOC of 1.9/10, while EYPT trades at $13.50 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).